Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 211 to 225 of 537 results for syndrome

  1. Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (TA914)

    Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency in adults.

  2. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

  3. Percutaneous transforaminal endoscopic lumbar discectomy for sciatica (HTG412)

    Evidence-based recommendations on percutaneous transforaminal endoscopic lumbar discectomy for sciatica in adults. This involves removing part of the damaged spinal disc to relieve the symptoms of sciatica.

  4. Low back pain and sciatica in over 16s: assessment and management (NG59)

    This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.

  5. The geko device for reducing the risk of venous thromboembolism (HTG344)

    Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism.

  6. Transvaginal mesh repair of anterior or posterior vaginal wall prolapse (HTG456)

    Evidence-based recommendations on transvaginal mesh repair of anterior or posterior vaginal wall prolapse. This involves inserting a mesh to replace tissue that has weakened and caused the pelvic organs to drop down (prolapse) into the vagina.

  7. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (TA1139)

    Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment in adults.

  8. Irreversible electroporation for treating liver metastases (HTG304)

    Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.

  9. Laparoscopic uterine nerve ablation (LUNA) for chronic pelvic pain (HTG150)

    Evidence-based recommendations on laparoscopic uterine nerve ablation (LUNA) for chronic pelvic pain. This involves the destruction of a small segment of ligament that carries nerve fibres within the pelvis.

  10. Therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury (HTG221)

    Evidence-based recommendations on therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury. This involves cooling either the baby's head or whole body to prevent brain damage.

  11. In moderate OSAHS, which clinical and physiological phenotypes predict treatment response to customised mandibular advancement splints?

    from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s Number NG202...

  12. Women's and reproductive health guidelines

    - Menopause: diagnosis and management - Polycystic ovary syndrome: diagnosis and management Development of new guideline ongoing...

  13. Mandibular advancement splints for severe OSAHS: What is the clinical and cost effectiveness of mandibular advancement splints for managing severe OSAHS?

    from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s Number NG202...

  14. Mandibular advancement splints for mild symptomatic OSAHS and moderate OSAHS: In mild symptomatic OSAHS, which clinical and physiological phenotypes predict treatment response to customised mandibular advancement splints?

    from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s Number NG202...